Our study indicates that blocking the UGCG–B4GalT5 axis can reduce pathological heart hypertrophy; therefore, these UGCG inhibitors may also be used to treat pressure overload-induced remodeling of the heart. The gene discussed is B4GALT5; the disease is cardiac hypertrophy.